INVA Innoviva Inc
Company Analysis
Latest News
🔴 Innoviva is trading 6% down today after quarterly revenue miss and unexpected loss
Innoviva is trading at $20.08, down 5.55%, after quarterly revenue missed consensus and the company reported a loss instead of an expected profit. -...
Innoviva Posts a Big Earnings Beat and 45% Sales Growth — But Can the Core Business Outrun a Shrinking Royalty Stream?
Shares of Innoviva surged 8.2% in pre-market trading to $23.00 after the diversified biopharma company delivered a third-quarter earnings beat on November 4,...
🟢 Innoviva is trading 8.2% up in pre-market after adjusted earnings beat estimates
Innoviva is trading 8.2% up at $23.00 in pre-market on November 5 after its November 4 results, where adjusted earnings beat estimates. - Revenue was $106.1...
Innoviva’s third quarter 2026 revenue of $106.1M missed estimates despite 45% growth in U.S. product sales
Innoviva reported a top-line miss for the third quarter of 2026, with total revenue declining 1.6% year-over-year. The company recorded a significant net loss...
Innoviva Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Analysts expect Innoviva to report Q3 2026 revenue of approximately $115.31 million and an EPS of $0.49, while the current stock price of $21.22 remains...
🟢 Innoviva is trading 6.47% up in pre-market with catalyst still unclear
Innoviva is trading at $22.71, up 6.47% in pre-market; the catalyst remains unclear. - No company-specific announcement, earnings release, filing, or analyst...
🔴 Innoviva is trading 10.25% down in pre-market; no company-specific announcement identified
Innoviva is trading 10.25% down at $19.00, with no new company-specific announcement identified for August 26, 2026. - Investor relations lists its latest...
🔴 Innoviva is trading 8.1% down in pre-market after $161.0 million investment fair-value decline
Innovava is trading at $19.00 (-8.12%) with no new company-specific announcement identified for August 11, 2026. • The August 5 earnings report showed $119.6...
Innoviva second quarter 2026 revenue rose 19% behind 46% growth in specialty therapeutics sales
Innoviva reported second quarter 2026 total revenue of $119.6 million, a 19% increase year-over-year. While the core royalty portfolio provided stable cash...